Related Experiment Video
Updated: Aug 9, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Clinico-Pathological and Clinical Outcomes of Soft Tissue Sarcoma With FUS-TFCP2 or EWSR1-TFCP2 Fusions: A Case
Karishma Agarwal1, Sameer Rastogi2, Sunil Pasricha3
1Radiation Oncology, Max Super Speciality Hospital, Saket, New Delhi, IND.
Abstract:
Tumours with FUS-TFCP2 or EWSR1-TFCP2 mutations are classified under rhabdomyosarcomas at present. These tumours are exceedingly rare and on pathology show spindled to epitheloid cells, with a predisposition for gnathic bone involvement, with an aggressive outcome. We hereby present a total of four patients harbouring a FUS-EWSR1 TFCP2 mutation recruited over a period of 2.5 years. All four reported cases are males with median age of 26.5 years (range 22-37 years). Primary site in all four cases was bone, with three being of head and neck origin and one with a primary in femur. Three of our patients were misdiagnosed outside. All of our patients received chemotherapy at some point and three out of four cases received radiation with a good response (two patients with palliative doses of radiation also responded well). All four patients are alive at follow-up, two on treatment for metastatic disease. This is the first Indian case series reporting the clinicopathological details in patients with TFCP2 mutations.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Tumor Immunotherapy

